Association between promoter polymorphisms of matrix metalloproteinase-1 and risk of gastric cancer

Growing evidences show that matrix metalloproteinase-1 (MMP1) plays important roles in tumorigenesis and cancer metastasis. The interactions between MMP1−1607 1G>2G polymorphism and risk of gastric cancer (GC) have been reported, but results remained ambiguous. To determine the association between MMP1−1607 1G>2G polymorphism and risk of GC, we conducted a meta-analysis and identified the outcome data from all the research papers estimating the association between MMP1−1607 1G>2G polymorphism and GC risk, which was based on comprehensive searches using databases such as PubMed, Elsevier Science Direct, Excerpta Medica Database (EMBASE), and Chinese National Knowledge Infrastructure (CNKI). The fixed-effects model was used in this meta-analysis. Data were extracted, and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. In this meta-analysis, six studies involving 1,377 cases and 1,543 controls were included. We identified the significant association between MMP1−1607 1G>2G polymorphism and GC risk for allele model (OR =1.05; 95% CI, 1.01−1.08), for dominant model (OR =1.11; 95% CI, 1.08−1.15), and for recessive model (OR =1.06; 95% CI, 0.98−1.14). In summary, our analysis demonstrated that MMP1−1607 1G>2G polymorphism was significantly associated with an increased risk of GC.